– USA, NY – Rheonix Inc. today announced the appointment of Dr. Roy Proujansky, M.D., and Dr. Irving Nachamkin, DrPH, MPH, to its board of directors.
“I’m honored to welcome Drs. Proujansky and Nachamkin to our board,” saidfounder and CEO, Dr. Greg Galvin. “They join Rheonix at an exciting time as we provide critical testing solutions to address the pandemic and broaden our clinical diagnostic portfolio. The addition of these directors complements our board of directors’ skills and experiences, and we are confident they will provide valuable perspectives as we continue to execute our growth strategy.”
About Dr. Roy Proujansky
Dr. Proujansky is an experienced healthcare physician executive, having served for over 30 years in physician, hospital and health system leadership positions. While at Nemours Children’s Health System, his roles included chief executive for the physician practice, COO for the Nemours Children’s Health System and chief executive for the duPont Hospital for Children and Delaware Valley Operations. Dr. Proujansky has previously served as a board member of the Delaware Healthcare Association, the Delaware Health Sciences Alliance and as a member of the Children’s Hospital Association’s quality and safety committee.
“I’m thrilled to join Rheonix, a company that is providing accurate and low-cost diagnostic capability to clinics, hospitals and other laboratories at a time of such great need,” said Dr. Proujansky.
Dr. Proujansky received his undergraduate and medical degrees from Northwestern University and an MBA from the University of Massachusetts. He completed training in pediatrics at the University of Connecticut and fellowships in gastroenterology and nutrition and infectious disease research at Harvard Medical School. He is a professor of pediatrics at the Sidney Kimmel College of Medicine of Thomas Jefferson University.
About Dr. Irving Nachamkin
Dr. Nachamkin is professor emeritus of pathology and laboratory medicine and the immediate past director of the division of laboratory medicine and associate director of the clinical microbiology laboratory at the Perelman School of Medicine and Hospital of the University of Pennsylvania in Philadelphia. Dr. Nachamkin has been the principal or co-principal investigator of numerous research programs while at Penn and author or co-author of over 220 peer-reviewed papers, reviews and book chapters. He is an expert in clinical microbiology with a focus on laboratory diagnostics, molecular diagnostics in infectious diseases and laboratory management.
“It’s an honor to join the Rheonix board of directors and work with a fabulous team dedicated to improving laboratory diagnostics with exciting testing platforms and an expanded portfolio of tests,” said Dr. Nachamkin.
He received his undergraduate degree in medical laboratory science from the University of Bridgeport and his MPH and DrPH from the University of North Carolina. He completed postgraduate training as a fellow in medical and public health laboratory microbiology at the Medical College of Virginia and at the Penn Medicine Clinical Leadership Academy. Dr. Nachamkin is a fellow of the American Academy of Microbiology, Infectious Diseases Society of America and College of Physicians of Philadelphia.
About Rheonix
Rheonix has developed the suite of Encompass workstations, fully automated systems that provide highly multiplexed sample-to-answer molecular testing for use in clinical, research and applied testing laboratories. With minimal hands-on time, the Encompass systems offer true walkaway simplicity. Rheonix’s growing portfolio offers multiplexed testing solutions including the Beer SpoilerAlert assay, the most comprehensive beer spoilage panel available; the Listeria PatternAlert assay, a rapid method for Listeria strain typing; and the NGS OnePrep solution, a fully integrated and automated DNA extraction and library prep solution. The Rheonix STI TriPlex Assay and Rheonix Encompass MDx workstation are currently undergoing FDA 510(k) review.
In April 2020, Rheonix received U.S. Food and Drug Administration Emergency Use Authorization for the Rheonix COVID-19 MDx assay, a fully automated testing solution that delivers same-day results in authorized testing laboratories. In December 2020, Rheonix received expanded EUA for saliva as a sample type, enabling simplified, safer and less expensive sample collection. In order to meet evolving COVID-19 testing demand, Rheonix has increased production capacity by greater than thirtyfold.
For more information : https://rheonix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
